IWM, NVDQ: Big ETF Inflows
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2024
0mins
Should l Buy INSM?
Source: NASDAQ.COM
ETF Inflows: The NVDQ ETF experienced the largest increase in inflows, adding 2,890,000 units, which represents a 36.6% rise in outstanding units.
Author's Opinion Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 144.000
Low
162.00
Averages
219.50
High
263.00
Current: 144.000
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: The IBB ETF has a 52-week low of $107.43 and a high of $179.64, with the latest trade at $163.76, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, aiding in trend assessment and more informed investment choices.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual components within the ETF.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
INSM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: INSM's 52-week low is $60.40 per share, while the high is $212.75, with the last trade at $143.57, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Market Trend Observation: The current stock price of $143.57 is close to the 52-week low, which may suggest a lack of investor confidence in the company's future growth, necessitating close monitoring of market dynamics to assess investment risks.
- Technical Indicator Warning: INSM's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, potentially leading to increased selling pressure and impacting short-term stock performance.
- Investor Sentiment Assessment: Despite the current stock price being below the 200-day moving average, investors should carefully evaluate market sentiment and the company's fundamentals to decide whether to increase or decrease their holdings at this time.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Plan: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, which aims to comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's incentive measures closely tied to market performance.
- Vesting Arrangements: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring employee stability and loyalty during their tenure with the company.
- Company Background: Insmed is a global biopharmaceutical company focused on developing first-class therapies to improve the lives of patients with serious diseases, demonstrating its leadership in the biopharmaceutical industry and ongoing commitment to innovation.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: The IBB ETF has a 52-week low of $107.43 and a high of $179.64, with the latest trade at $163.76, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, aiding in trend assessment and more informed investment choices.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual components within the ETF.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
INSM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: INSM's 52-week low is $60.40 per share, while the high is $212.75, with the last trade at $143.57, indicating significant volatility in its stock price over the past year, reflecting varying market expectations for its future performance.
- Market Trend Observation: The current stock price of $143.57 is close to the 52-week low, which may suggest a lack of investor confidence in the company's future growth, necessitating close monitoring of market dynamics to assess investment risks.
- Technical Indicator Warning: INSM's stock price has fallen below its 200-day moving average, typically viewed as a technical sell signal, potentially leading to increased selling pressure and impacting short-term stock performance.
- Investor Sentiment Assessment: Despite the current stock price being below the 200-day moving average, investors should carefully evaluate market sentiment and the company's fundamentals to decide whether to increase or decrease their holdings at this time.
See More
Insmed Grants Inducement Awards to 85 New Employees
- Inducement Award Plan: Insmed has granted inducement awards to 85 new employees under its 2025 Inducement Plan, which aims to comply with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to attracting talent.
- Stock Units and Options: The new employees received a total of 68,947 restricted stock units and options to purchase 4,710 shares at an exercise price of $149.33 per share, reflecting the company's incentive measures closely tied to market performance.
- Vesting Arrangements: The restricted stock units have a four-year vesting schedule with 25% vesting annually, while the options vest gradually over four years, ensuring employee stability and loyalty during their tenure with the company.
- Company Background: Insmed is a global biopharmaceutical company focused on developing first-class therapies to improve the lives of patients with serious diseases, demonstrating its leadership in the biopharmaceutical industry and ongoing commitment to innovation.
See More
